AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31009327 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated PDS
Number of subjects: 890
Study 31009327 — intervention group
Group type: COMPARATOR
Intervention: Standard PDS
Number of subjects: 890
Study 30360970 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for 12 weeks
Number of subjects: 116
Study 30360970 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally once daily for 12 weeks
Number of subjects: 116
Study 26861663 — intervention group
Group type: EXPERIMENTAL
Intervention: NewBrace (brace designed using CAD/CAM and FEM)
Number of subjects: 40
Study 26861663 — intervention group
Group type: COMPARATOR
Intervention: CtrlBrace (brace designed using conventional CAD/CAM)
Number of subjects: 40
Study 23360100 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU AVP (administered nasally)
Number of subjects: 36
Study 23360100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered nasally)
Number of subjects: 36
Study 20874726 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen (Ketotifen)
Number of subjects: 103
Study 20874726 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 103
Study 19153534 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene modifier (LM)
Number of subjects: 18
Study 17125829 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching primers (Clearfil SE Bond, Clearfil Protect Bond)
Number of subjects: 5
Study 17125829 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesives (Single Bond, Prime&Bond NT)
Number of subjects: 5
Study 17125829 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesive (One-up Bond F)
Number of subjects: 5
Study 17125829 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after storage in oil
Number of subjects: 5
Study 17125829 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching primers (especially Clearfil Protect Bond)
Number of subjects: 5
Study 15305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 2000 mg m(‐2) day(‐1)
Number of subjects: 28
Study 15305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 1800 mg m(‐2) day(‐1)
Number of subjects: 28
Study 15305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (various dose levels)
Number of subjects: 28
Study 11284824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 75
Study 11284824 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 75
Study 9082037 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (PA) diet
Number of subjects: 151
Study 9082037 — intervention group
Group type: COMPARATOR
Intervention: Lard (LA) diet
Number of subjects: 151
Study 9082037 — intervention group
Group type: COMPARATOR
Intervention: Peanut oil (PE) diet
Number of subjects: 151
Study 8400675 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IDM) 50 mg every 8 hours for 4 days
Number of subjects: 20
Study 8400675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IDM or other non-steroidal anti-inflammatory drug)
Number of subjects: 20
Study 8400675 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IDM)
Number of subjects: 20
Study 2870233 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1
Study 2870233 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 1
Study 29703528 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplements (fish oil and flaxseed oil)
Number of subjects: 150
Study 29703528 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 26321018 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of arginine vasopressin 1A and 1B receptor agonist
Number of subjects: 109
Study 26321018 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 109
Study 26321018 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 109
Study 26321018 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 109
Study 23972565 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MIS) total knee arthroplasty
Number of subjects: 86
Study 23972565 — intervention group
Group type: COMPARATOR
Intervention: Standard medial parapatellar approach (control)
Number of subjects: 86
Study 23033299 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam dressings with silver (Group A)
Number of subjects: 26
Study 23033299 — intervention group
Group type: COMPARATOR
Intervention: Foam dressings without silver (Group B)
Number of subjects: 26
Study 20237499 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCSolver method (oscillometric method)
Number of subjects: 302
Study 20237499 — intervention group
Group type: COMPARATOR
Intervention: SphygmoCor method (tonometric system)
Number of subjects: 302
Study 18341378 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (300 mg/m2 intravenously before 131I administration)
Number of subjects: 80
Study 18341378 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group (Control)
Number of subjects: 80
Study 18341378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose of 131I
Number of subjects: 80
Study 15724236 — intervention group
Group type: EXPERIMENTAL
Intervention: nateglinide
Number of subjects: 16
Study 15724236 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 12213943 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin (1750 anti-Xa units given once daily)
Number of subjects: 440
Study 12213943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 10605275 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Balters appliance (USA UNC, Chapel Hill)
Number of subjects: 3
Study 10605275 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐bow activator Type I (Germany WWU Münster)
Number of subjects: 3
Study 10605275 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated malocclusions, USA UNC, Chapel Hill)
Number of subjects: 3
Study 7485128 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g intravenously after every dialysis session for 6 months)
Number of subjects: 24
Study 7485128 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 2025806 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made braces (Generation II Polyaxial Knee Cage and Lenox Hill Derotation Brace)
Number of subjects: 10
Study 2025806 — intervention group
Group type: COMPARATOR
Intervention: Off-the-shelf braces
Number of subjects: 10
Study 6988106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (200 micrograms total: 25 micrograms/actuation, 2 actuations into each nostril twice a day)
Number of subjects: 60
Study 6988106 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400 micrograms total: 50 micrograms/actuation, 1 actuation in each nostril four times a day)
Number of subjects: 60
Study 31461146 — intervention group
Group type: EXPERIMENTAL
Intervention: Free self-tests
Number of subjects: 3996
Study 31461146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tests for US $0.50
Number of subjects: 3996
Study 31461146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tests for $1, $2, and $3
Number of subjects: 3996
Study 31461146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based distribution
Number of subjects: 3996
Study 31461146 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotional messages
Number of subjects: 3996
Study 28336454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis targeting the infrapatellar branch of the saphenous nerve (IPBSN)
Number of subjects: 180
Study 28336454 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 180
Study 25880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group program of eight sessions every 3 months led by trained nurses with tailored semi-automated SMS support.
Number of subjects: 2300
Study 25880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Short educational program for primary care professionals including a decision support tool and monthly feedback report.
Number of subjects: 2300
Study 25880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of educational interventions for patients and professionals.
Number of subjects: 2300
Study 25880498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2300
Study 25880498 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3) will also be assessed for secondary endpoints: cardiovascular risk factors, macrovascular and microvascular diabetes complications, quality of life, psychological outcomes, diabetes knowledge, and healthcare utilization.
Number of subjects: 2300
Study 23414626 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 39
Study 23414626 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 39
Study 21325473 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day: 177 mL soy milk, 126 g tofu, or 23 g soy nuts) for 6 months
Number of subjects: 96
Study 21325473 — intervention group
Group type: COMPARATOR
Intervention: Low-soy diet (<3 servings/week) for 6 months
Number of subjects: 96
Study 19919978 — intervention group
Group type: EXPERIMENTAL
Intervention: Corin I555(P568) allele
Number of subjects: 354
Study 19919978 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination isosorbide-dinitrate/hydralazine
Number of subjects: 354
Study 17578938 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-level 2-Hz TENS
Number of subjects: 33
Study 17578938 — intervention group
Group type: COMPARATOR
Intervention: Sensory-level 80-Hz TENS
Number of subjects: 33
Study 17578938 — intervention group
Group type: COMPARATOR
Intervention: Subliminal 80-Hz TENS
Number of subjects: 33
Study 15090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tones delivered at the ipsilateral ear (right) at increasing intensities (60, 70, 80 dBA)
Number of subjects: 10
Study 15090059 — intervention group
Group type: COMPARATOR
Intervention: Concurrent tone of constant intensity delivered dichotically at the contralateral ear (left)
Number of subjects: 10
Study 15090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral tone fundamental frequency similar to ipsilateral tone
Number of subjects: 10
Study 15090059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening conditions
Number of subjects: 10
Study 11179529 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 214
Study 9752815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged polychemotherapy
Number of subjects: 18000
Study 9752815 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-containing regimens
Number of subjects: 18000
Study 8017815 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic Ingram Trocar
Number of subjects: 70
Study 8017815 — intervention group
Group type: EXPERIMENTAL
Intervention: Add‐a‐Cath
Number of subjects: 70
Study 8017815 — intervention group
Group type: COMPARATOR
Intervention: Standard Foley catheter
Number of subjects: 70
Study 2807359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (0.36 to 0.65 mg/kg/day)
Number of subjects: 37
Study 2807359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (0.66 to 0.99 mg/kg/day)
Number of subjects: 37
Study 2807359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Metoprolol (1 to 1.81 mg/kg/day)
Number of subjects: 37
Study 2807359 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Goteberg Metoprolol trial and MIAMI trials (200 mg/day)
Number of subjects: 37
Study 1103934 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole in cream and powder base
Number of subjects: 45
Study 1103934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 45
Study 31926893 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium glass, 1540 nm laser treatment 24 hours before surgery
Number of subjects: 11
Study 31926893 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11
Study 31147247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion THA
Number of subjects: 389
Study 28608804 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3-milk
Number of subjects: 32
Study 28608804 — intervention group
Group type: EXPERIMENTAL
Intervention: PhyS-milk
Number of subjects: 32
Study 25882987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 647
Study 25882987 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 647
Study 24384588 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir (ATV/r)
Number of subjects: 269
Study 24384588 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 269
Study 24384588 — intervention group
Group type: COMPARATOR
Intervention: Abacavir-lamivudine (ABC/3TC)
Number of subjects: 269
Study 24384588 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir DF-emtricitabine (TDF/FTC)
Number of subjects: 269
Study 24384588 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased lean body mass (LBM)
Number of subjects: 269
Study 21387016 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants susceptible to auditory illusions
Number of subjects: 0
Study 21387016 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not prone to illusory discontinuity
Number of subjects: 0
Study 19016092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention
Number of subjects: 44
Study 19016092 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 44
Study 16542606 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS positive symptoms
Number of subjects: 100
Study 16542606 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS negative symptoms
Number of subjects: 100
Study 16542606 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression risk profile scores
Number of subjects: 100
Study 16542606 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores
Number of subjects: 100
Study 12855928 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity stationary cycling (EXER)
Number of subjects: 21
Study 12855928 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d spironolactone (DIUR)
Number of subjects: 21
Study 12855928 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diuretic (EXDI)
Number of subjects: 21
Study 12855928 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 21
Study 11239617 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone followed by 800 microg vaginal misoprostol at 24, 48, or 72 h
Number of subjects: 2302
Study 8703859 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.1 microgram/min)
Number of subjects: 19
Study 8703859 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (peripheral vasoconstrictor)
Number of subjects: 19
Study 8703859 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (non-specific vasodilator)
Number of subjects: 19
Study 1355209 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplement (HE) providing 1950 kJ (465 kcal) during the last trimester of pregnancy
Number of subjects: 0
Study 1355209 — intervention group
Group type: COMPARATOR
Intervention: Low energy supplement (LE) providing 218 kJ (52 kcal) during the last trimester of pregnancy
Number of subjects: 0
Study 1355209 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplement (HE)
Number of subjects: 0
Study 6347428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (975 mg/day)
Number of subjects: 176
Study 6347428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (225 mg/day)
Number of subjects: 176
Study 6347428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 176
Study 30352778 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 FA (3.36 eicosapentaenoic acid [EPA] + docosahexaenoic acid)
Number of subjects: 49
Study 30352778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g olive oil)
Number of subjects: 49
Study 27805266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexualized appearance of the victim
Number of subjects: 0
Study 27805266 — intervention group
Group type: COMPARATOR
Intervention: Non-sexualized appearance of the victim
Number of subjects: 0
Study 25515725 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to prasugrel or ticagrelor from clopidogrel
Number of subjects: 11999
Study 25515725 — intervention group
Group type: COMPARATOR
Intervention: Continuation on prasugrel or ticagrelor
Number of subjects: 11999
Study 25515725 — intervention group
Group type: COMPARATOR
Intervention: Continuation on clopidogrel
Number of subjects: 11999
Study 24463756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 60
Study 24463756 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 60
Study 22962202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S.
Number of subjects: 128
Study 19291926 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone injection (Group A)
Number of subjects: 32
Study 19291926 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) (Group B)
Number of subjects: 32
Study 17236859 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality training with an angled-telescope simulator (EndoTower; Verefi Technologies, Elizabethtown, PA)
Number of subjects: 19
Study 17236859 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 19
Study 15007746 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) measurement
Number of subjects: 12
Study 15007746 — intervention group
Group type: COMPARATOR
Intervention: Motion correction
Number of subjects: 12
Study 11506215 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually designed physical training programme
Number of subjects: 282
Study 11506215 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-place stress management
Number of subjects: 282
Study 11506215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study 9802368 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide turbohaler (1600 micrograms)
Number of subjects: 22
Study 9802368 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg)
Number of subjects: 22
Study 7949230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 20
Study 7949230 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 2462442 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 2462442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 28966208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 51
Study 28966208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27513296 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 0
Study 27513296 — intervention group
Group type: COMPARATOR
Intervention: Endovascular revascularization (ER)
Number of subjects: 0
Study 24881803 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free jet injector (Stratis; PharmaJet)
Number of subjects: 1250
Study 24881803 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe
Number of subjects: 1250
Study 24220660 — intervention group
Group type: EXPERIMENTAL
Intervention: KT intervention including a three-day skills training workshop and multifaceted workplace supports (paid EBP time, mentoring, system changes, access to an online research synthesis tool)
Number of subjects: 135
Study 24220660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 135
Study 20631214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-error trials
Number of subjects: 0
Study 20631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Some high-error trials
Number of subjects: 0
Study 20631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-error trials
Number of subjects: 0
Study 20631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of high- and low-error trials
Number of subjects: 0
Study 20631214 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent force field
Number of subjects: 0
Study 20631214 — intervention group
Group type: COMPARATOR
Intervention: Incongruent force field
Number of subjects: 0
Study 17545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded first molar tubes (n = 181) bonded with Rely‐A‐Bond after a 30‐second etch
Number of subjects: 110
Study 17545300 — intervention group
Group type: COMPARATOR
Intervention: Cemented bands (n = 186) with Intact glass ionomer cement (GIC)
Number of subjects: 110
Study 15136063 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 0
Study 15136063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Probucol and Ticlopidine)
Number of subjects: 0
Study 15136063 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11214732 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (SO) 15 mL daily for 14 months
Number of subjects: 120
Study 11214732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod-liver oil (CLO) 15 mL daily for 14 months
Number of subjects: 120
Study 11214732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplement)
Number of subjects: 120
Study 9548121 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise until fatigued
Number of subjects: 20
Study 9548121 — intervention group
Group type: COMPARATOR
Intervention: Rested state
Number of subjects: 20
Study 7808826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadhesive semipermeable dressing
Number of subjects: 15